Home » BCS Editorials » Breaking the Barrier: The Benefits and Drawbacks of TAVI in Low-Surgical Risk Patients
Breaking the Barrier: The Benefits and Drawbacks of TAVI in Low-Surgical Risk Patients
Debar Rasoul
Take home messages
Transcatheter aortic valve implantation (TAVI) is a well-established therapy for patients with severe aortic stenosis (AS) where traditional surgical aortic valve replacement surgery (SAVR) carries intermediate or higher operative risk. (ACS).
Recent trials have shown that TAVI is non-inferior and even superior to SAVR in patients with low surgical risk. However, concerns remain that any complications could have a greater long-term impact on younger patients.
There is favourable 8-year TAVI valve longevity data with non-inferiority to bioprosthetic surgical valve longevity.
Conduction disorders, aortic regurgitation, coronary artery access and considerations of future approaches to repeat aortic valve intervention remain the key obstacles.
Cardiologists in Heart Teams will need to consider not only the immediate patient care but also anticipate future developments and challenges to ensure optimal outcomes for their patients in the lifelong management of AS.
